Hanmi Pharmaceutical has terminated its contract with Genexine to produce COVID-19 vaccines

This article is translated by AI company Flitto and Alhpa Biz neural machine translation technology

폴리

hoondork1977@alphabiz.co.kr | 2023-02-28 05:30:50

서울 송파구 방이동 한미약품 본사 (사진 = 연합뉴스)

[Alpha Biz=(Chicago) Reporter Paul Lee] Hanmi Pharmaceutical announced on the 27th that it has agreed to terminate the contract for consignment production of Genexine COVID-19 vaccines.

According to the public announcement, the main reason for the termination of the contract is Genexine's decision to stop developing the COVID-19 vaccine.

With the termination of the contract, the amount of termination is 23.4 billion won, excluding performance performance from the existing contract amount.

Hanmi Pharmaceutical has terminated its contract with Genexine to produce COVID-19 vaccines

This article is translated by AI company Flitto and Alhpa Biz neural machine translation technology

많이 본 기사